Table 1. Comparative studies.
Study | Study design and setting | Eligibility criteria | Intervention | Comparator | COPD definition | COPDa/eligibleb | Limitations |
---|---|---|---|---|---|---|---|
Bunker 200922 | RCT: nurse-led case finding using spirometry versus usual care in four practices (recruitment dates not reported). | Inclusion criteria: ever smokers aged 40–80 years. Exclusion criteria: known diagnosis of COPD, cognitive impairment, non-English speaking and <2 visits to practice in the preceding year. | Case finding arm: spirometry (unclear whether pre- or post-BD) performed by practice nurses. | Routine care. | FEV1/FVC<70% (unclear whether pre- or post-BD). | Case finding: 10/400 (2.5%) Routine care: 1/408 (0.2%). Difference in yield=2.3% (95% CI 0.7 to 3.9%). | Method of randomisation was not described. Inadequate outcome ascertainment. Outcome assessors were not blinded. Unclear whether intervention groups were comparable. |
Dirven 201323 | Cluster RCT: patient versus practice-managed scoring of a screening questionnaire in 16 general practices from May to September 2012. | Inclusion criteria: age 40–70 years. Exclusion criteria: previous diagnosis of asthma, COPD or significant lung disease. Patients using oxygen supplementation and those with impaired mobility were also excluded. | Patient-managed arm Stage 1: patients were mailed the Respiratory Health Screening Questionnaire, self-calculated risk of COPD and advised to consult GP if score was >19.5. Stage 2: post-BD spirometry for subjects scoring >19.5. | Practice-managed arm Stage 1: patients were mailed the questionnaire, but scoring was performed by healthcare staff. Stage 2: post-BD spirometry on subjects scoring >19.5. | Post-BD FEV1/FVC<0.7 and physician’s clinical evaluation. | Patient managed: 25/6393 (0.4%). Practice managed: 48/3715 (1.3%). Difference in yield=0.9% (95% CI 0.5 to 1.3%). | Unclear whether intervention groups were comparable (although practices were stratified by socioeconomic status). Unclear whether outcome assessors were blinded. |
Haroon 201316 | RCT: active versus opportunistic case finding in two general practices from May 2010 to January 2011. | Inclusion criteria: ever smokers aged 35–79 years. Exclusion criteria: prior diagnosis of COPD or asthma. | Active arm Stage 1: postal screening questionnaire. Stage 2: pre-BD spirometry in subjects with symptoms. | Opportunistic arm Stage 1: opportunistic screening questionnaire provided at routine primary care visits. Stage 2: pre-BD spirometry in subjects with symptoms. | Pre-BD FEV1/FVC<0.7 with FEV1<80% predicted, lack of reversibility (reversibility defined as increase in FEV1 of 200 ml and 15% from pre-BD FEV1) and presence of respiratory symptoms. | Active: 10/815 (1.2%). Opportunistic: 6/819 (0.7%). Difference in yield=0.5% (95% CI −0.5 to 1.5%). | Unclear whether outcome assessors were blinded. Poor spirometry attendance. |
Konstantikaki 201125 | Non-randomised controlled trial: open spirometry programme versus case finding strategy in 24 semirural general practices from November 2008 to October 2009. | Inclusion criteria: >30 years. Exclusion criteria: history of respiratory tract infection in previous 4 weeks and inability to perform spirometry. | Open spirometry arm: public invitation through local advertisements offering free spirometry to people with chronic respiratory symptoms. | Case finding strategy: primary care physicians identified patients with a probable diagnosis of COPD in their daily practice and spirometry performed by research team. | History of exposure to noxious particles or gases, particularly smoking, compatible symptoms and post-BD FEV1/FVC<0.7. | Open spirometry: 76/1084 (7.0%). Case finding: 56/219 (25.6%). Difference in yield=18.6% (95% CI 12.6 to 24.6%). | No randomisation. Poor description of recruitment, selection criteria and spirometry. |
Abbreviations: BD, bronchodilator; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RCT, randomised controlled trial.
Subjects newly diagnosed with COPD.
Eligible subjects.